Valbiotis: upbeat after successful clinical trial

(CercleFinance.com) - Valbiotis gained over 11% on the Paris market on Wednesday morning, following last night's announcement of the success of its Phase II/III trial in arterial hypertension.


The trial demonstrated efficacy in reducing systolic blood pressure (SBP) in individuals with mild untreated hypertension, as the study's primary endpoint was met, with a 'significant' difference compared to placebo.

The international study involved 410 participants, and was conducted over three months of supplementation.

Valbiotis points out that hypertension (high blood pressure) is a major cause of premature death worldwide, affecting around 1.13 billion people.

After Lipidrive (ex-Totum-070) for hypercholesterolemia and Totum-63 for pre-diabetes and early stages of type 2 diabetes, Totum-854 is the third Valbiotis compound to obtain proof of clinical efficacy.

From Valbiotis' point of view, this success validates its scientific approach based on innovative combinations of plant-based active ingredients.

The share price is currently up nearly 12%, posting the second-best performance on the Paris market. With this increase, the company's market capitalization exceeds 22 million euros.

Copyright (c) 2024 CercleFinance.com. All rights reserved.